ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "costs"

  • Abstract Number: 252 • 2019 ACR/ARP Annual Meeting

    Treatment Sequences, Effectiveness, and Costs of Tumor Necrosis Factor Inhibitor Cycling Compared with Swapping to a Novel Disease-modifying Anti-rheumatic Drug in Rheumatoid Arthritis Patients

    Aliza Karpes 1, Zhigang Duan 2, Hui Zhao 2, Lincy Lal 3, Wenyaw Chan 3, Maria E. Suárez-Almazor 4, Sharon Giordano 2, John Swint 3 and Maria Lopez-Olivo2, 1School of Public Health, The University of Texas Health Science Center at Houston, Dallas, TX, 2The University of Texas, MD Anderson Cancer Center, Houston, TX, 3School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 4Department of Rheumatology/Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX , USA., Houston, TX

    Background/Purpose: To evaluate the sequences of therapeutic drugs used by rheumatoid arthritis (RA) patients whose initial tumor necrosis factor inhibitor (TNFi) therapy failed, as well…
  • Abstract Number: 1124 • 2019 ACR/ARP Annual Meeting

    The Direct and Indirect Costs of Illness Associated with Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review

    Jennifer Lofland1, Pamela Berry 2, Feng Pan 2, Chetan Karyekar 3, Hannah Guiang 4, Rebecca McTavish 4 and Melissa Thompson 4, 1Janssen Scientific Affairs, LLC, Spring House, PA, 2Janssen Scientific Affairs, LLC, Horsham, PA, 3Janssen Global Services, LLC, Horsham, PA, 4Cornerstone Research Group, Inc, Burlington, ON, Canada

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. SLE tends to peak during prime working years, resulting in a high economic burden due…
  • Abstract Number: 1138 • 2019 ACR/ARP Annual Meeting

    Outpatient Costs and Evaluation and Management (E&M) Expenditure Trends in Rheumatoid Arthritis (RA) Patients Treated with Biologic Therapies in US Community Practices

    Colin Edgerton1, Janna Radtchenko 2 and V. Michael Holers 3, 1Articularis Healthcare, Charleston, 2Trio Health, La Jolla, CA, 3University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver

    Background/Purpose: RA is an autoimmune disease affecting over 1.5 million Americans. Biologic disease-modifying antirheumatic drugs (bDMARDs) expanded treatment choices for RA patients (pts) in the…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.